AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis

AbbVie (ABBV) announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes inflammation of the medium to large arteries. GCA marks the eighth approved indication for Rinvoq.Rinvoq (15 mg, once daily) is the first JAK inhibitor to be approved in the EU for the GCA indication and is also the first oral advanced therapy for treating the condition. The approval for GCA was based on data from the ...